4987S-10* Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiatio

Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation.

Type of Study
Heart & Vascular - Other Trials
Short Description

The study is designed to assess if incorporating genotype testing results of CYP2C9 and VKORC1 gene variants into a warfarin dosing protocol can change the number of adverse events related to Warfarin in older subjects (>65) beginning warfarin therapy.

Status
Open
Principal Investigator
John Petersen II, MD
Eligibility Notes

Age 65 or older beginning Warfarin therapy (doses 0-3 taken at the time of enrollment)

Start Date
10/26/2010
Contact Name
Jeremy Gillis or Jennifer Nagel
Phone
206-215-2437
Alternate Phone
206-386-6462
Email
jeremy.gillis@swedish.org
Alternate Email
jennifer.nagel@swedish.org